Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy

• Published in: The Journal of infectious diseases 2018-02, Vol.217 (5), p.840-850
• Main Authors: Costa, Rúbia S, Carvalho, Lucas P, Campos, Taís M, Magalhães, Andréa S, Passos, Sara T, Schriefer, Albert, Silva, Juliana A, Lago, Ednaldo, Paixão, Camilla S, Machado, Paulo, Scott, Phillip, Carvalho, Edgar M
• Format: Article
• Language: English
• Subjects: Major and Brief Reports
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/jix627

Early in L braziliensis infection, progression from a papule to an ulcer is observed despite antimony therapy. Here, we show that dysfunction in the immune modulation and enhancements of inflammatory cytokines are associated with ulcer development. Abstract Background Early cutaneous leishmaniasis (ECL) is characterized by a nonulcerated papular lesion and illness duration less than 30 days. Approximately 4 weeks later, the cutaneous leishmaniasis (CL) ulcers appear. We were surprised to find that failure after antimony therapy (Sb5) is higher in ECL than CL. We hypothesize that the inflammatory response in ECL patients may increase during Sb5 therapy, which leads to treatment failure. Methods A cohort of 44 ECL patients infected by Leishmania braziliensis was established to evaluate the response to Sb5 and to compare immunologic responses in ECL patients with CL and healthy subjects. Results A hierarchical clustering based on cytokine levels showed a weak positive correlation between proinflammatory cytokine levels and those patients that failed Sb5 treatment. Although Sb5 therapy decreased interferon-γ and tumor necrosis factor levels in CL patients, we were surprised to find that an increase in these cytokines was observed in ECL patients. Moreover, interleukin (IL)-10 was less able to down-modulate immune responses in ECL. Conclusions The enhanced production of proinflammatory cytokines, due in part to the decreased ability of IL-10 to down-modulate immune response during therapy in ECL, promotes the development and persistence of leishmania ulcer despite antimony therapy.